Literature DB >> 22452635

Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.

Andreas Josefsson1, Pernilla Wikström, Lars Egevad, Torvald Granfors, Lars Karlberg, Pär Stattin, Anders Bergh.   

Abstract

OBJECTIVE: The aim of this study was to explore whether vascular density and tumour cell proliferation are related to the risk of prostate cancer death in patients managed by watchful waiting.
MATERIAL AND METHODS: From a consecutive series of men diagnosed with prostate cancer at transurethral resection in 1975-1990, tissue microarrays (TMAs) were constructed. A majority of men had no metastases at diagnosis and were followed by watchful waiting (n = 295). The TMAs were stained for Ki67, endoglin and factor VIII-related antigen (vWf).
RESULTS: In univariate Cox analyses, increased Ki67 index, endoglin vascular density and vWf vascular density were associated with shorter cancer-specific survival. Ki67 index and endoglin vascular density added independent prognostic information to clinical stage, estimated tumour size and Gleason score (GS) in multivariate Cox analysis. In GS 6 tumours, high Ki67 index and high endoglin vascular density identified patients with poor outcome. After 15 years of follow-up not a single man out of 34 men with low staining for both markers (35% of all GS 6 tumours) had died of prostate cancer, in contrast to 15 prostate cancer deaths among the remaining 63 men with GS 6 tumours (65% cumulative risk of prostate cancer death). vWf vascular density in benign areas was a prognostic marker in GS 6 and 7 tumours.
CONCLUSIONS: Men with GS 6 tumours with both low Ki67 index and endoglin vascular density staining scores have a low risk of progression. Additional studies are needed to test whether these two markers can be applied to core biopsies to select patients suitable for surveillance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452635     DOI: 10.3109/00365599.2012.669791

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  21 in total

1.  Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.

Authors:  Adriana C Vidal; Frank Duong; Lauren E Howard; Emily Wiggins; Stephen J Freedland; Neil A Bhowmick; Jun Gong
Journal:  Anticancer Res       Date:  2020-03       Impact factor: 2.480

Review 2.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

3.  Personalized management in low-risk prostate cancer: the role of biomarkers.

Authors:  Siebren Dijkstra; Agus Rizal A H Hamid; Gisèle H J M Leyten; Jack A Schalken
Journal:  Prostate Cancer       Date:  2012-12-13

4.  Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.

Authors:  Hanibal Hani Adamo; Sofia Halin Bergström; Anders Bergh
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

5.  TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.

Authors:  Christina Hägglöf; Peter Hammarsten; Kerstin Strömvall; Lars Egevad; Andreas Josefsson; Pär Stattin; Torvald Granfors; Anders Bergh
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.

Authors:  Mariateresa Cipriano; Jenny Häggström; Peter Hammarsten; Christopher J Fowler
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

7.  Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression.

Authors:  Peter Hammarsten; Mariateresa Cipriano; Andreas Josefsson; Pär Stattin; Lars Egevad; Torvald Granfors; Christopher J Fowler
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

8.  ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome.

Authors:  Peter Hammarsten; Johanna Winther; Stina H Rudolfsson; Jenny Häggström; Amar Karalija; Lars Egevad; Torvald Granfors; Christopher J Fowler
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

9.  Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.

Authors:  Jenny Häggström; Mariateresa Cipriano; Linus Plym Forshell; Emma Persson; Peter Hammarsten; Nephi Stella; Christopher J Fowler
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

10.  Adaptive (TINT) Changes in the Tumor Bearing Organ Are Related to Prostate Tumor Size and Aggressiveness.

Authors:  Hanibal Hani Adamo; Kerstin Strömvall; Maria Nilsson; Sofia Halin Bergström; Anders Bergh
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.